UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2016

_____

Commission File Number: 001-37891

AC IMMUNE SA

(Exact name of registrant as specified in its charter)

EPFL Innovation Park
Building B
1015 Lausanne, Switzerland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F X Form 40-F _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes _____ No X

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes _____ No X

Annual Ordinary Shareholders' Meeting Results

On November 15, 2016, AC Immune SA ("**AC Immune**") held its annual Ordinary Shareholders' Meeting. The presentation that was given at the Ordinary Shareholders' Meeting is attached hereto as Exhibit 99.1. The final results of each of the agenda items submitted to a vote of the shareholders are as follows:

Agenda Item 1: Approval of the Annual Report, Annual Financial Statements and Consolidated Financial Statements of AC Immune SA for the year 2015

AC Immune shareholders approved the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements of AC Immune SA under IFRS for the year 2015.

Agenda Item 2: Appropriation of Gain

AC Immune shareholders approved the application of the net profit of the year 2015 in the amount of KCHF 20,173 against the loss brought forward of KCHF 45,103 resulting in a reduced new balance of loss brought forward of KCHF 24,930.

Agenda Item 3: Discharge of the Members of the Board of Directors and the Executive Board

AC Immune shareholders approved the discharge the Board and the Executive Board of their liabilities for their activities in the financial year 2015.

Agenda Item 4: Compensation for the Members of the Board of Directors and the Executive Committee

AC Immune shareholders approved:

A. The total maximum amount of non-performance-related compensation for the members of the Board of Directors covering the period from 15 November 2016 to 30 June 2017, *i.e.*, CHF 286,080 (cash base compensation plus social security costs);

B. The maximum grant of equity or equity linked instruments for the members of the Board of Directors from 15 November 2016 to 30 June 2017 with maximum value of CHF 460,000 (equity value plus social security costs);

C. The total maximum amount of non-performance-related cash compensation for the members of the Executive Committee from 15 November 2016 to 30 June 2017, *i.e.*, CHF 836,790 (cash base compensation plus social security costs);

D. The total maximum amount of variable compensation for the members of the Executive Committee for the current year 2016, *i.e.*, CHF 667,000 (cash compensation plus social security costs); and

E. The maximum of equity or equity linked instruments for the members of the Executive Committee from 15 November 2016 to 30 June 2017, *i.e.*, CHF 2,001,000 (equity value plus social security costs).

Agenda Item 5: 2016 Stock Option and Incentive Plan

AC Immune shareholders approved the 2016 Stock Option and Incentive Plan including a maximum of 2,057,740 options for common shares under the 2016 Stock Option and Incentive Plan.

Agenda Item 6: Election of the Members of the Board

AC Immune shareholders approved the re-election of Martin Velasco as member and as Chairman of the Board, Peter Bollmann, Friedrich von Bohlen, Andrea Pfeifer and Detlev Riesner as members of the Board of Directors and the election of Thomas Graney as new member of the Board of Directors, each until the end of the next Ordinary General Meeting.

Agenda Item 7: Election to the Compensation, Nomination & Corporate Governance Committee

AC Immune shareholders approved the election of Detlev Riesner, Martin Velasco and Tom Graney as members of the Compensation, Nomination & Corporate Governance Committee, each until the end of the next Ordinary General Meeting.

Agenda Item 8: Re-Election of the independent proxy

AC Immune shareholders approved the election of Bugnion Ballansat Ehrler, represented by Gérald Virieux, as AC Immune's independent proxy until the end of the next Ordinary General Meeting.

Agenda Item 9: Re-Election of the Auditors

AC Immune shareholders approved the re-election of Ernst & Young SA, in Lancy, for a term of office of one year.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AC IMMUNE SA

By: /s/ Andrea Pfeifer
Name: Andrea Pfeifer
Title: Chief Executive Officer

By: /s/ George Pavey
Name: George Pavey
Title: Chief Financial Officer

Date: November 15, 2016

EXHIBIT INDEX

Exhibit Number	Description
99.1	Annual Ordinary Shareholders' Meeting presentation

Exhibit 99.1

NOVEL THERAPIES

AND DIAGNOSTICS FOR NEURODEGENERATIVE DISEASES WITH FOCUS ON ALZHEIMER'S

AC Immune

Annual General Meeting I November 15, 2016

www.acimmune.com

Vision

Become a global leader in neurodegenerative diseases leveraging dual proprietary technology platforms to develop breakthrough therapies

SupraAntigen™

Vaccines and antibodies specific to disease causing conformations

Morphomer™

Conformation-sensitive small molecules

AC Immune – A leader in neurodegenerative diseases

Highlights

1. Large and growing neurodegenerative disease market driven by significant unmet medical need

2. Proprietary technology platforms (SupraAntigen, Morphomer) as engines for sustained growth

3. Diverse product pipeline with complementary diagnostic agents in clinical development (active and passive immunotherapies, small molecules)

4. Phase 3 lead product, crenezumab, with compelling phase 2 data and favorable safety profile

5. Multiple high-profile strategic alliances with leading industry partners provide external validation and resources (Roche/Genentech, J&J/Janssen, Piramal, Nestlé/NIHS[1], Biogen)

AC Immune

(1) Nestle Institute of Health Sciences SA

Alzheimer's disease

Early diagnosis translates into earlier treatment and better outcome



- The future treatment paradigm for neurodegenerative diseases may involve **different disease-modifying treatments used at various points in the progression of the disease**
- Possible **combination** therapies:
  - Passive immunization targeting Abeta (e.g., crenezumab) together with anti-tau antibodies
  - Immunotherapies and small molecules targeting Abeta or tau

Misfolded proteins are generally recognized as leading causes of neurodegenerative diseases

AC Immune's therapies intervene at key points in the disease pathway



AC Immune's technology leadership

Product-focused and highly productive platforms drive growth

SupraAntigen™

Vaccines and antibodies specific to disease causing conformations

Morphomer™

Conformation sensitive small molecules

Immunotherapy against conformation-specific targets

- Antibodies and vaccines highly selective for conformational targets
- Rapid antibody response
- Acceptable safety profile – T-cell independent mechanism does not trigger T-cell correlated inflammatory response
- 4 products in clinical development: crenezumab, ACI-24, ACI-35, anti-Tau antibody

Generation of conformation specific small molecules



- Rational chemical design for small molecules that target CNS diseases
- Robust library of compounds with desirable properties including brain penetration
- Protein propagation inhibitors
- Proof-of-concept in animal models
- 5 development candidates

Strategy to create value and mitigate risk



Note: Neuro-orphan = neurodegenerative orphan disease, PD = Parkinson's Disease, PSP = Progressive Supranuclear Palsy, LBD = Lewy Body Dementia

AC Immune's robust pipeline

Driven by our proprietary technology platforms



(1) AD = Alzheimer's disease
(2) In process of completing a Phase 1/2a study
(3) AD and cognitive impairment associated with Down syndrome
(4) Currently in first in-man study. Piramal Imaging is expected to advance this program into Phase 1 clinical development in 2016. PET = positron emission tomography
(5) IVD = in vitro diagnostic

Biologics | Small molecules | Diagnostics

AC Immune

Highlights and achievements 2015/2016

Company

- Received upfront payment from Janssen deal on ACI-35 signed in December 2014 (01/2015)
- Awarded grant from The Michael J. Fox Foundation for Parkinson's disease to support development of alpha-synuclein PET-tracers (02/2015)
- Received milestone payment from Genentech for selection of anti-Tau lead antibody for further development towards clinical trials (07/2015)
- Received milestone payment from Genentech/Roche for decision to move crenezumab into phase 3 clinical development in Alzheimer's disease (07/2015)
- Signed collaboration agreement focused on early diagnosis of AD in CSF and blood with Nestlé Institutes of Health Sciences (09/2015)
- Signed R&D collaboration agreement with Biogen focused on development of PET-ligands for alpha-synuclein and TDP-43 (04/2016)
- Secured CHF 42.7 million Series E crossover financing round from group of highly regarded investors (05/2016)
- Received milestone payment from Genentech for start of Phase 1 of anti-Tau antibody
- Secured net proceeds of $ 70.5 million* (CHF 69.4 million) from Initial Public Offering at NASDAQ

* Including 15% greenshoe

Highlights and achievements

Clinical stage programs

Clinical stage programs

- **Crenezumab**[1]: Commenced patient recruitment of CREAD Phase 3 clinical trial in Q1 2016
- **ACI-24 in DS:** Initiated Phase 1 clinical trial in collaboration with the University of California San Diego in people with Down syndrome and published scientific publication in PLOS one
- **ACI-35**[2]**:** Completed enrollment of all patients (cohort 1-5) of extended Phase 1b study
- **Tau-PET imaging agent**[3]: Commenced First-in-Man clinical studies after approval of IND and developed improved lead compounds with best-in-class properties
- **Anti-Tau antibody**[1]: Dosed first patient in Phase 1 clinical trial for Alzheimer's disease

Developed under out-licensing agreements with (1) Genentech, (2) Janssen and (3) Piramal

Highlights and achievements

Pre-clinical stage programs

- **Morphomer Tau (AD):** Demonstrated dose-dependent reduction of pathological Tau and improvement of memory
- **Morphomer Abeta (glaucoma):** Revealed promising efficacy with enhanced development properties
- **Morphomer alpha-synuclein (PD):** Showed dose dependent reduction of pathological aggregated alpha-synuclein, rescuing of neuronal function and improved safety
- **Alpha-synuclein-PET imaging agent:** Revealed promising candidates with high selectivity for alpha-synuclein aggregates and Lewy bodies and good brain penetration and clearance

Developed under out-licensing agreements with (1) Genentech, (2) Janssen and (3) Piramal

Strategy for value creation

CONTINUE to leverage our dual platform technologies to efficiently advance commercially viable product candidates

INVEST resources to further establish leadership in neurodegenerative diseases and complement existing technology leads

- Accelerate the advancement of our diagnostic portfolio
- Continue to explore new targets

EVOLVE strategy to develop late stage assets in-house

EXPAND into other neurodegenerative and neuro-orphan diseases

- Pursuing neuro-orphan indications may enable us to obtain a streamlined regulatory approval pathway and favorable reimbursement treatment of any approved product

Financial Overview

AC Immune

Financial overview (IFRS)

Key financial data

(all figures in CHF millions excepts EPS data)	For the Year Ended December 31 2015	2014	Change
Income statement			
Revenues	39.1	30.3	29.1%
R&D expenses	17.0	16.1	5.8%
G&A expenses	3.4	3.4	(0.5%)
Total operating expenses	20.5	19.6	+4.7%
Operating income	18.6	10.7	73.8%
Financial result, net	1.6	-	n/m
Net income	20.3	10.7	88.7%
EPS – basic	0.47	0.25	88.0%
EPS - diluted	0.44	0.24	83.3%

Financial overview (IFRS)

Key financial data

(all figures in CHF millions)	As of December 31, 2015	2014
Balance Sheet		
Cash	76.5	3.3
Accounts receivable	0.3	25.9
Total assets	**79.9**	**30.3**
Total shareholders' equity	71.0	23.5
Total liabilities	8.9	6.8
Total liabiliities and shareholders' equity	**79.9**	**30.3**

Financial overview (IFRS)

Key financial data

(all figures in CHF millions)	For the Nine Months Ended September 30, 2016	2015	Change
Income statement			
Revenues	21.8	38.8	(43.8%)
R&D expenses	18.7	11.3	65.4%
Total operating expenses	23.2	13.8	67.1%
Net income	(2.3)	25.9	n/m

	As at September 30, 2016	2015
Balance sheet		
Cash and cash equivalents	157.6	53.7
Total assets	160.7	55.1
Total equity	146.2	48.2